VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
2.350
-0.010 (-0.42%)
At close: Dec 10, 2025, 4:00 PM EST
2.290
-0.060 (-2.54%)
After-hours: Dec 10, 2025, 6:38 PM EST
VivoSim Labs Revenue
VivoSim Labs had revenue of $28.00K in the quarter ending September 30, 2025, a decrease of -6.67%. This brings the company's revenue in the last twelve months to $140.00K, up 35.92% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$140.00K
Revenue Growth
+35.92%
P/S Ratio
34.58
Revenue / Employee
$10,769
Employees
13
Market Cap
6.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 144.00K | 35.00K | 32.11% |
| Mar 31, 2024 | 109.00K | -261.00K | -70.54% |
| Mar 31, 2023 | 370.00K | -1.13M | -75.33% |
| Mar 31, 2022 | 1.50M | - | - |
| Mar 31, 2021 | - | - | - |
| Mar 31, 2020 | 2.20M | -895.00K | -28.96% |
| Mar 31, 2019 | 3.09M | -1.51M | -32.85% |
| Mar 31, 2018 | 4.60M | 373.00K | 8.82% |
| Mar 31, 2017 | 4.23M | 2.75M | 185.23% |
| Mar 31, 2016 | 1.48M | 912.00K | 159.72% |
| Mar 31, 2015 | 571.00K | 192.00K | 50.66% |
| Mar 31, 2014 | 379.00K | -818.00K | -68.34% |
| Dec 31, 2012 | 1.20M | 228.00K | 23.53% |
| Dec 31, 2011 | 969.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Dec 31, 2010 | 603.41K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VIVS News
- 4 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 7 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 7 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 7 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire
- 8 months ago - VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - GlobeNewsWire
- 8 months ago - VivoSim to Carry Forward Organovo 3D Bioprinting - GlobeNewsWire
- 9 months ago - Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements - GlobeNewsWire
- 9 months ago - Organovo Provides Business Update - GlobeNewsWire